SPLICING MUTATIONS PREDICT ANEMIA PROGRESSION AND INFERIOR SURVIVAL IN RUXOLITINIB‑TREATED MYELOFIBROSIS PATIENTS (SIE 2026) - Oct 6, 2026 - Abstract #C033; Pres time: Sep 21, 2026; 03:40 PM - 05:10 PM; Location: HALL 3; P | "MF pts harboring SpM exhibit an anemic phenotype and a 2 fold higher risk for RUX-emergent and worsening anemia, identifying a vulnerable molecularly defined subgroup with inferior outcomes and higher progres- sion risk. These findings support exploring alternative, ane- mia focused strategies for this pt subset."
Clinical • Anemia • Fibrosis • Hematological Disorders • Hematological Malignancies • Immunology • Myelofibrosis • Thrombocytopenia • ASXL1 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2
|
|
C. Sartor1; F. Branzanti2; M. Bonifacio3; Em. Elli4; E. Abruzzese5; M. Tiribelli6; E. Morsia7; M. Farina8; G. Benevolo9; E. Beggiato10; N. Pugliese11; A. Tieghi12; E. Scalzulli13; F. Cavazzini14; A. Iurlo15; M. Crugnola16; A. Duminuco17; D. Cattaneo15; M. Trawinska6; C. Bosi18; A. Dedola1,2; F. Salvatore1,2; D. Cavallina1,2; N. Severi1,2; F. Cavalca4; D. Cilloni19; M. Bocchia20; G. Caocci21; C. Fava22; F. Pane11; Ga. Palumbo23; M. Breccia13; F. Palandri1
|